Aeterna Zentaris Inc. – Nasdaq: AEZS
Aeterna Zentaris shares traded up over 20% today on the belief that the company will be completed with Phase 3 testing and begin commercialization of two products in 2017. AEZS, traded on the Nasdaq, experienced volumes ten times normal in today’s trading session and the shares settled at $3.15.
Canadian-based Aeterna Zentaris has two drugs far along in its pipeline. The first is Macrilen, a drug designed to evaluate adults for growth hormone deficiency, is expected to deliver top-line results once the final stages of pivotal clinical testing are completed in early-2017. The other drug in development is Zoptrex, a treatment for advanced endometrial cancer, which has been re-engineered from an established chemotherapeutic agent. The new treatment is rumored to be safer in terms of side-effects, and reportedly provides extended chances for survival for women with advanced endometrial cancer.
AEZS shares have experienced negative EPS for the last five years but year-on-year EPS losses have been narrowing. In 2011 AEZS lost $168.75 per share. That loss narrowed to $18.18 in 2015. AEZS sales have been inconsistent and in 2015 Aeterna Zenatris posted just $500k. Two firms follow Aeterna Zentaris and both rate AEZS shares as a “Strong Buy” with a price target of $8.75.
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
|Last Price a/o 6:09 PM EST||$ 3.20|
|Market Cap (mlns)||$ 37.55|
|Shares Outstanding (mlns)||11.92|
|Share Float (mlns)||11.61|
|Short Interest Ratio||2.73|